BACKGROUND: Representative data on the current management of patients with acute coronary syndromes (ACS) are of high interest. The EPICOR registry aimed to prospectively collect such real-life data with particular focus on antithrombotic drug utilization and outcomes. METHODS: As part of the international prospective EPICOR registry, 29 hospitals in Germany documented 296 patients with ST-elevation myocardial infarction (STEMI)-ACS and 333 with unstable angina or non-STEMI (NSTEMI)-ACS surviving the hospital phase. The statistical analysis was performed in a descriptive manner. The ClinicalTrials.gov identifier is NCT01171404. RESULTS: The mean age of patients was 62 ± 13 years, and 77.4 % were men. Treatment with antithrombotic agents was initiated in the prehospital phase in 50.7 % of STEMI and 33.3 % of NSTEMI patients. During the hospital stay (median 7.0 days), cardiac catheterization was performed in 97.6 %, percutaneous coronary intervention in 85.6 %, thrombolysis in 4.6 %, and coronary bypass surgery in 2.7 % patients. The use of acetylic salicylic acid (ASA) was reported in 95.6 % vs. 96.1 %, clopidogrel in 60.8 % vs. 73.0 %, prasugrel in 45.6 % vs. 22.5 %, any GP IIb/IIIa inhibitor in 52.4 % vs. 18.9 % [any dual combination of ASA+(clopidogrel/prasugrel)in 94.0 vs. 91.0 %], statins in 94.6 % vs. 92.2 %, beta blockers in 96.3 % vs. 94.6 %, and ACE-I/ARB in 91.6 % vs. 87.7 % of STEMI vs. NSTEMI patients, respectively. Combined use of the five drug classes recommended in the guidelines-ASA, P2Y12 antagonists, statin, beta blocker, and ACE-I/ARB-was reported in 81.1 % vs. 69.4 % of STEMI vs. NSTEMI patients, respectively. CONCLUSION: In Germany a high proportion of patients with ACS are treated according to current guidelines, receiving primary revascularization as well as antithrombotic drugs and other agents for prevention of secondary events; associated bleeding complications were less frequent as compared with published registries.
BACKGROUND: Representative data on the current management of patients with acute coronary syndromes (ACS) are of high interest. The EPICOR registry aimed to prospectively collect such real-life data with particular focus on antithrombotic drug utilization and outcomes. METHODS: As part of the international prospective EPICOR registry, 29 hospitals in Germany documented 296 patients with ST-elevation myocardial infarction (STEMI)-ACS and 333 with unstable angina or non-STEMI (NSTEMI)-ACS surviving the hospital phase. The statistical analysis was performed in a descriptive manner. The ClinicalTrials.gov identifier is NCT01171404. RESULTS: The mean age of patients was 62 ± 13 years, and 77.4 % were men. Treatment with antithrombotic agents was initiated in the prehospital phase in 50.7 % of STEMI and 33.3 % of NSTEMI patients. During the hospital stay (median 7.0 days), cardiac catheterization was performed in 97.6 %, percutaneous coronary intervention in 85.6 %, thrombolysis in 4.6 %, and coronary bypass surgery in 2.7 % patients. The use of acetylic salicylic acid (ASA) was reported in 95.6 % vs. 96.1 %, clopidogrel in 60.8 % vs. 73.0 %, prasugrel in 45.6 % vs. 22.5 %, any GP IIb/IIIa inhibitor in 52.4 % vs. 18.9 % [any dual combination of ASA+(clopidogrel/prasugrel)in 94.0 vs. 91.0 %], statins in 94.6 % vs. 92.2 %, beta blockers in 96.3 % vs. 94.6 %, and ACE-I/ARB in 91.6 % vs. 87.7 % of STEMI vs. NSTEMI patients, respectively. Combined use of the five drug classes recommended in the guidelines-ASA, P2Y12 antagonists, statin, beta blocker, and ACE-I/ARB-was reported in 81.1 % vs. 69.4 % of STEMI vs. NSTEMI patients, respectively. CONCLUSION: In Germany a high proportion of patients with ACS are treated according to current guidelines, receiving primary revascularization as well as antithrombotic drugs and other agents for prevention of secondary events; associated bleeding complications were less frequent as compared with published registries.
Authors: Alessandro Sciahbasi; Vittoria Rizzello; Lucio Gonzini; Simona Giampaoli; Cesare Greco; Giuseppe Di Pasquale; Gian Francesco Mureddu; Antonio Di Chiara; Ernesto Lioy; Alessandro Boccanelli Journal: Eur J Prev Cardiol Date: 2012-09-05 Impact factor: 7.804
Authors: Michael J Lim; Kim A Eagle; Joel M Gore; Frederick A Anderson; Omar H Dabbous; Rajendra H Mehta; Christopher B Granger; Keith A A Fox; Frederick A Spencer; Robert J Goldberg Journal: Am J Cardiol Date: 2005-10-01 Impact factor: 2.778
Authors: Ralf Birkemeyer; Andreas Rillig; Annette Koch; Tomislav Miljak; Markus Kunze; Udo Meyerfeldt; Wolfgang Steffen; Martin Soballa; Carsten Ranke; Roland Prassler; Albert Benzing; Werner Jung Journal: Clin Res Cardiol Date: 2010-07-06 Impact factor: 5.460
Authors: Shaun G Goodman; Wei Huang; Andrew T Yan; Andrzej Budaj; Brian M Kennelly; Joel M Gore; Keith A A Fox; Robert J Goldberg; Frederick A Anderson Journal: Am Heart J Date: 2009-08 Impact factor: 4.749
Authors: William R Lewis; Eric D Peterson; Christopher P Cannon; Dennis M Super; Kenneth A LaBresh; Kathleen Quealy; Li Liang; Gregg C Fonarow Journal: Arch Intern Med Date: 2008-09-08
Authors: Brendan J Doyle; Henry H Ting; Malcolm R Bell; Ryan J Lennon; Verghese Mathew; Mandeep Singh; David R Holmes; Charanjit S Rihal Journal: JACC Cardiovasc Interv Date: 2008-04 Impact factor: 11.195
Authors: N P G Hoedemaker; M E Ten Haaf; J C Maas; P Damman; Y Appelman; J G P Tijssen; R J de Winter; A W J van 't Hof Journal: Neth Heart J Date: 2017-04 Impact factor: 2.380
Authors: Helmut Trimmel; Thomas Bayer; Wolfgang Schreiber; Wolfgang G Voelckel; Lukas Fiedler Journal: Scand J Trauma Resusc Emerg Med Date: 2018-05-09 Impact factor: 2.953